References
- Gottlieb J.A., Baker L.H., Quagliana J.M. Chemotherapy of sarcomas with a combination of Adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 1972; 30: 1632
- Gottlieb J.A., Baker L.H., O'Bryan R.M., et al. Adriamycin (NSC-123-127) used alone and in combination for soft tissue and bone sarcoma. Cancer Chemother. Rep. 1975; 6: 271
- Bramwell V.H., Mouridsen H.T., Santoro A., et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcoma. Eur. J. Cancer Clin. Oncol. 1987; 23: 311–321
- Therapeutic Progress in Ovarian Cancer, Testicular Cancer, and the Sarcomas, A.T. van Oosterom, F.M. Muggia, F.J. Cleton. Leiden University Press (Martinus Nijhoff, Kluwer Academic Publishers): Boston&Dordrecht. 1980; 507
- Antman K.H., Crowley J., Balcerzak S.P., et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 1993; 11: 1276–1285
- Venveij T., van Oosterom A.T., Somers R., et al. Chemotherapy in the multidisciplinary approach to soft tissue sarcoma. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. Ann. Oncol. 1992; 3: S75
- Judson I., Radford J.A., Harris M., et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2001; 37: 870–877
- Garcia A.A., Kempf R.A., Rogers M., Muggia F.M. A phase II study of doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann. Oncol. 1998; 9: 1131–1133
- Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344: 1052–1056
- Blanke C.D., von Mehren H., Joensuu P., et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy STI571, in patients with unresectable or metastsatic gastrointestinal stromal tumors (GISTS) expressing c-kit (CD117). Proc. ASCO 2001; 20: 1a, (Abstract 1)
- Hensley M.L., Venkatraman E., Maki R., Spriggs D. Docetaxel plus gemcitabine is active in leiomyosarcoma: results of a phase II trial. Proc. ASCO 2001; 20: 353s, (Abstract 1408)
- Maki, R. Ecteinascidin-743 (ET-743), a novel marine-derived chemotherapeutic agent with clinical activity against soft-tissue sarcoma. Presented at the Chemotherapy Foundation Symposium, New York, Nov 12, 2001.
- Casper E.S., Waltzman R.J., Schwartz G.K., Sugarman A., Pfister D., Ilson D., Woodruff J., Leung D., Bertino J.R. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Investig. 1998; 16(7)442–446
- Folkman, J. Presented at the Chemotherapy Foundation Symposium, New York, Nov 12, 2001.